The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Mendelian Randomization: Nature's Randomized Trial in the Post–Genome Era
Open accessAbstract
Despite several observational studies showing that lipoprotein(a), or Lp(a), is associated with myocardial infarction (MI) 1,2 , only circumstantial evidence exists regarding the causal nature of this association.Observational epidemiological studies, even with a sound prospective design, can provide hints to disease pathogenesis when the effect size is modest but cannot provide definitive evidence for causal relationships.Much of the current understanding of the causal factors in cardiovascular disease, such as the role of LDL, has been confirmed by randomized clinical trials (RCT) 3,4 .However, RCTs are not always feasible.In the case of Lp(a), the modest effect size and the lack of specific Lp(a) lowering therapy are major obstacles to obtaining causal evidence for its role in cardiovascular disease.In this issue of JAMA, Kamstrup and colleagues 5 provide insights using a "Mendelian randomization" approach and provide evidence for the causal role of Lp(a) in MI.This study elegantly demonstrates how Mendelian randomization can be used to improve the evidence for causality from observational studies and highlights the advantages and limitations of such an approach.The study by Kamstrup et al., can be viewed as a form of natural "randomized trial" of plasma Lp(a) level on myocardial infarction, with a few important differences from traditional clinical trials.Instead of using drug therapy to decrease plasma Lp(a) levels, genetic variation in the lipoprotein apo(a) gene, LPA, that controls plasma levels of Lp(a) are used."Randomization", which minimizes the effect of confounding variables, is achieved through the random assortment of these LPA gene variants from parents to offspring that occurs duringgamete formation and conception.In this way, because LPA variants are randomly assigned, they are unlikely to associate with other nongenetic factors, such as lifestyle factors, that could act as confounders, thereby providing an unbiased assessment of the role of Lp(a) in MI.Lp(a) represents an excellent example of a genetic exposure that can be evaluated using the Mendelian randomization approach.Such an approach requires highly accurate quantitation of the triangulation of three associations: LPA gene variants and serum Lp(a) levels, serum Lp(a) levels and myocardial infarction, and LPA gene variants and myocardial infarction.Much of the population variation (30-60%) in Lp(a) levels is explained by the number of copy number variants, known as KIV-2 repeats, a form of structural variation, in the LPA gene 5, 6 .With increasing number of KIV-2 repeats in the LPA gene, plasma levels of Lp(a) are reduced.In the Copenhagen City Heart Study (CCHS), the authors demonstrate that this
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Genetically elevated C-reactive protein and ischemic vascular disease
Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707402 · Cited by 839
Ebrahim, S., & Davey Smith, G. (2008) · Human Genetics · doi:10.1007/s00439-007-0448-6 · Cited by 410
Bennet, A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.598 · Cited by 281
Cited by
Using multiple genetic variants as instrumental variables for modifiable risk factors
Palmer, T. M., Lawlor, D. A., Harbord, R. M., Sheehan, N. A., Tobias, J. H., Timpson, N. J., Smith, G. D., & Sterne, J. A. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280210394459 · Cited by 1,289
A robust and efficient method for Mendelian randomization with hundreds of genetic variants
Burgess, S., Foley, C. N., Allara, E., Staley, J. R., & Howson, J. M. M. (2020) · Nature Communications · doi:10.1038/s41467-019-14156-4 · Cited by 681
Relton, C. L., & Davey Smith, G. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr233 · Cited by 567
Zuber, V., Grinberg, N. F., Gill, D., Manipur, I., Slob, E. A. W., Patel, A., Wallace, C., & Burgess, S. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.04.001 · Cited by 532
Use of allele scores as instrumental variables for Mendelian randomization
Burgess, S., & Thompson, S. G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt093 · Cited by 452
Metadata
- Authors
- Thanassoulis, G., & O’Donnell, C. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-06-10
- Volume
- 301
- Issue
- 22
- Pages
- 2386
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2071135141
- Cited by
- 209
- References
- 7
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.